Clinical Trial Update: Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating regorafenib combined with nivolumab in unresectable hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Regorafenib (regorafenib)
• nivolumab (nivolumab)

Snippet

Sponsor: Asan Medical Center | Conditions: Carcinoma, Hepatocellular, Hepatoma | Phase 2 | Status: COMPLETED